# Revivicor

其经10个基因编辑的UHeart已获FDA批准，可推进EXPRESS临床试验——一项针对猪心异种移植的自适应I/II/III期设计，此前已在FDA扩大准入下完成史上首例活体患者猪心移植。

Source: https://cn.bioecon.ru/companies/revivicor/
Updated: 2026-07-03

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 监管批准 | UHeart 异种移植 EXPRESS 临床试验于2026年5月15日获 FDA 许可 | https://investingnews.com/united-therapeutics-corporation-announces-fda-clearance-to-proceed-with-uheart-xenotransplantation-clinical-trial/, https://ir.unither.com/press-releases/2026/05-15-2026-230017490, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthr-announces-fda-clearance-to-proceed-with-uheart-xenotransplantation-clinical-trial.pdf |
| 生产基地 | 位于弗吉尼亚州Christiansburg的临床规模无病原体设施 | https://apnews.com/article/pig-organ-transplant-xenotransplant-revivicor-ad400e7f1d30c2722456eb92e641449f, https://www.vtcrc.com/gene-editing-pigs-for-human-transplants/ |
| 产能 | Christiansburg工厂每年约生产125个器官 | https://apnews.com/article/pig-organ-transplant-xenotransplant-revivicor-ad400e7f1d30c2722456eb92e641449f, https://www.vtcrc.com/gene-editing-pigs-for-human-transplants/ |
| 营收 | 2026年第二季度为$7.833亿 | https://ir.unither.com/press-releases/2026/08-05-2026-113027315, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/2q26-earnings-release.pdf |
| 员工人数 | 截至2025年12月31日，员工超过1,400人 [中等置信度] | https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/events-and-presentations/factsheet-2q26.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/4q25-factsheet.pdf |

独立来源: apnews.com, investingnews.com, ir.unither.com, vtcrc.com

## 技术

- [异种移植](https://cn.bioecon.ru/technology/xenotransplantation/)